



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

Date: November 7, 2023

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	---

Dear Sir/Madam,

**Subject: Press Release- Unaudited Financial Results for the quarter and half year ended September 30, 2023**

The Board of Directors of the Company at their Meeting held on November 7, 2023 has inter alia, considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2023.

Please find attached the Press Release with regard to the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

**For Supriya Lifescience Limited**

**Shweta Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A44973**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



## SUPRIYA LIFESCIENCE LTD.

Press Release for immediate distribution

### **Supriya Lifescience Ltd reports second consecutive quarter of robust growth Revenue increase 25% in Q2 FY24 to Rs. 140.09 Crore**

**Mumbai, November 7, 2023:** Supriya Lifescience Ltd. a cGMP-compliant company having a well-established presence in API Manufacturing with a focus on products of various therapeutic segments like – Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, AntiAsthmatics, etc is pleased to announce the release of its Un-audited financial statements for the Q2 FY24.

#### **Key Consolidated Financial Highlights:**

Particulars	Q2 FY24	Q2 FY23
Revenues (in Rs Cr)	140.09	112.17
Gross Profit (in Rs Cr)	78.45	65.28
EBITDA (in Rs Cr)	31.75	28.56
PAT (in RsCr)	23.88	16.86
PAT Margin	17%	15%
Quarterly EPS (in Rs)	2.97	2.10

#### **Key Highlights for Q2 FY24:**

- In the second quarter of FY24, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 25% YoY increase, reaching Rs. 140.09 crore compared to Rs. 112.17crore in Q2 FY23.
- Gross Profit for Q2 FY24 stood at Rs. 78.45 crore, reflecting a growth of 20% compared to Rs. 65.28 crore in Q2 FY23.
- EBITDA for Q2 FY24 reached Rs. 31.75 crore, as opposed to Rs. 28.56 crore in Q2 FY23, marking a growth of 11% (YoY).

- Furthermore, the Profit After Tax (PAT) for Q2 FY24 was recorded at Rs. 23.88 crore, compared to Rs. 16.86 crore in Q2 FY23, exhibiting a growth of 42%.
- PAT Margin has gone up to 17% in Q2FY24 compared to 15% in Q2 FY23
- The outstanding performance in this quarter was led by a robust growth in European market that contributed 44% to the Q2FY24 Revenue.
- Europe accounted for 39% of the company's revenue in H1FY24, marking a significant increase from the 24% recorded in H1FY23.

**Mr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd**, commenting on the results, said, “At Supriya, we believe that accessible, affordable and effective healthcare is a fundamental human right, and to this effect, especially in a country like ours, I’m pleased to announce that lately the company has signed two agreements with Kalinga Institute of Technology for the development of a one-of-its-kind novel oral cancer detection kit named Quickblue and a wound healing gel named GelHeal. As the company continues to introduce such versatile products that cater to unmet medical demands, led by a strong thrust in its R&D capabilities, we believe more and more of such products will establish Supriya Lifescience Ltd. as an integrated healthcare provider.”

GelHeal, a protein-based crosslinked hydrogel, is a gel-based lotion that was developed specifically for in-situ scaffolding, providing mechanical support to deep wounds and facilitating scar-free skin regeneration. Whereas, Quickblue, an oral cancer diagnosis kit, allows patients to discover cancer cells in minutes, which is a considerable advance over current traditional approaches such as biopsy.

**Mr. Wagh** further added, “The company is committed to building a pipeline of new products, which could extend it beyond its longstanding competence in the area of antihistamines and towards antidiabetics and other areas. Additionally, the company plans to patent new technologies and initiate projects for the Contract Development Manufacturing Organisation (CDMO) business, leading to potential long-term revenue growth.”

.....

**Disclaimer Statements** in this “Document” describing the company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be “forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

**About Supriya Lifescience Ltd:**

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India.

Backed by strong R&D, 14 active USDMFs, 8 active CEPs & Worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. The company's focus is to develop APIs and Intermediates for both Innovators, Generic companies and we also partner exclusively as CMO.

**For More Details:**

Krishna Raghunathan	Abhishek Chawande
Supriya Lifescience Ltd	Dentsu Creative PR
Mob: +91-9963027693	Mob: +91-9664516774
e-mail: <a href="mailto:cfo@supriyalifescience.com">cfo@supriyalifescience.com</a>	e-mail: <a href="mailto:abhishek.chawande@dentsu.com">abhishek.chawande@dentsu.com</a>